Girding For New GERD Therapies

Two biotech companies, Addex Pharmaceuticals and XenoPort, are in a tight race to develop successors to the generic or soon-to-be-generic blockbuster proton pump inhibitors. As the firms' drugs proceed through clinical trials, their respective outcomes are an object lesson for biotechs and pharmaceutical companies looking to enter a crowded space already well served by existing medicines.